Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution

The 3-year overall survival (OS) rate of patients with previously treated or untreated stage III or IV melanoma has by now reached 63% using ipilimumab and nivolumab therapy. However, immune-related adverse events (irAEs) of grade 3 or 4 occurred in 59% of patients leading to discontinuation of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleef, R., Nagy, R., Baierl, A., Bacher, V., Bojar, H., McKee, D. L., Moss, R., Thoennissen, N. H., Szász, M., Bakacs, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053148/
https://www.ncbi.nlm.nih.gov/pubmed/33151369
http://dx.doi.org/10.1007/s00262-020-02751-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053148/
https://www.ncbi.nlm.nih.gov/pubmed/33151369
http://dx.doi.org/10.1007/s00262-020-02751-0

Ejemplares similares